Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT06555263. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects With Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1
Study identification
- NCT ID
- NCT06555263
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Sutro Biopharma, Inc.
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Luveltamab tazevibulin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 20, 2024
- Primary completion
- Apr 30, 2025
- Completion
- Apr 30, 2025
- Last update posted
- Aug 21, 2025
2024 – 2025
United States locations
- U.S. sites
- 7
- U.S. states
- 5
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Health - Moores Cancer Center | La Jolla | California | 92037 | — |
| Georgetown University Medical Center - Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20057 | — |
| Florida Cancer Specialists & Research Institute (FCS) | Lake Mary | Florida | 32746 | — |
| Tampa General Hospital - Cancer Center of South Florida | Tampa | Florida | 33606 | — |
| HealthPartners Frauenshuh Cancer Center | Saint Louis Park | Minnesota | 55426 | — |
| HealthPartners Cancer Center at Regions Hospital | Saint Paul | Minnesota | 55101 | — |
| Mary Crowley Cancer Research | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06555263, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2025 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06555263 live on ClinicalTrials.gov.